novaxomx, a subsidiary of curasan, a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopedic surgery, has signed an exclusive license agreement with Lysatpharma. novaxomx has obtained the exclusive rights to use Lysatpharma’s patented “exosome” technology for the research of optimizing biomimetic osteoconductive carrier materials by biologizing them with exosomes.

novaxomx focuses on the research, development, certification, production, and marketing of disruptive, biosurgical therapies for use in musculoskeletal diseases and tissue regeneration. It’s ambition is to improve the carriers’ biofunctionality in regenerative processes such as non-union or delayed non-union fractures or bone fusion after spinal fusion procedures. Other possible applications include the treatment of chronic osteomyelitis, rheumatoid arthritis, or periodontal bone loss.

The bioactive nanovesicles are secreted from human stem cells or derived from autologous platelets. They are introduced with the carrier materials and enable intercellular communication, which is crucial for regenerative processes in the human body.

Leonie Früh, Business Development Manager at curasan AG, comments: “The license novaxomx has obtained from Lysatpharma allows novaxomx to take an interdisciplinary approach to develop disruptive, biosurgical products that fundamentally improve bone healing. We expect that curasan’s clinically proven products can then be used even more effectively for bone regeneration thanks to the targeted, innovative biologization option.”